Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Clinical trial NCT00699166 · COMPLETED

Trial details

NCT number: NCT00699166
Sponsor: Novartis
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Irritable Bowel Syndrome

Start date: 2004-04-01
Primary completion: 2005-09-01
Enrollment: 135

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.